We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » EMA Lessens Regulatory Burden for Sponsors of Biosimilars
EMA Lessens Regulatory Burden for Sponsors of Biosimilars
December 8, 2010
Sponsors of monoclonal antibody-based biosimilars may face fewer regulatory hurdles in the EU in light of a new draft guidance released by the European Medicines Agency (EMA).